Navigation Links
CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
Date:9/9/2008

LAS VEGAS, Sept. 9 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) today announces that its first US site is open for patient enrollment for its Phase II clinical trial for the treatment of severe coronary heart disease. In the coming weeks, CVBT anticipates announcing additional sites as they open for enrollment. For current details about the clinical sites participating in CVBT's Phase II heart trial, please visit http://www.cvbt.com.

In this Phase II trial, CVBT's drug candidate containing human Fibroblast Growth Factor-1 (FGF-1), will be injected into patients' hearts, stimulating a healing process called angiogenesis. The drug will be delivered using the NOGA(R) XP Cardiac Navigation system and the MyoStar(TM) injection catheter.

Subjects must be between 25 and 75 years of age with at least a 3 month history of chronic stable angina triggered by physical exertion and must have a Canadian Cardiovascular Society (CCS) anginal classification III or IV while receiving optimal medical therapy. Their treating cardiologist will have determined that they are generally not suitable for interventional therapy or bypass surgery.

"Developing a clinical trial protocol such as ours takes an extraordinary amount of time and effort, and I am pleased to finally open our Phase II heart trial for patient screening," said Daniel C. Montano, CVBT's President and CEO. "I expect additional investigators at other hospitals to begin screening patients in the coming weeks. Our target is 30 hospitals for this international Phase II heart trial."

About CardioVascular BioTherapeutics

CVBT (OTC Bulletin Board: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit http://www.cvbt.com.

For media inquiries please contact:

Allison Caplan, (702) 839-7200

acaplan@cvbt.com

For investor inquiries please contact:

Investor Relations, (702) 839-7220

investorrelations@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
2. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
5. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
6. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
7. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
10. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
11. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... FRANCISCO , March 29, 2017  Spiral ... option agreement with Bionure Farma, S.L. for the ... and to BN119 in the field of otolaryngology ... plus sales-based royalties. The agreement provides Spiral ... assets with a differentiated product profile. Under the ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... An ... braces. "The rubber bands used in conjunction with my braces always rubbed against ... design a way to prevent this problem." The O.B.S. was the result of ...
(Date:3/29/2017)... ... March 29, 2017 , ... Hamlin Dental Group, multi-location dental ... offering laser dental treatments. Dental lasers are safe and effective options, and can be ... and can improve the overall quality of care. , Dr. Hamid Reza of Hamlin ...
(Date:3/29/2017)... Richmond, VA (PRWEB) , ... March 29, 2017 , ... ... of its seventh North American office location in Richmond, Virginia, located at the Riverfront ... April 11, attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as it ... either don’t have access to a health care facility or a pharmacy within 60 minutes ... the United States or for many who are faced with health or personal issues that ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... elected representatives in state legislatures and Congress to protect parental rights and civil ... health and safety in America. , The demonstration coincides with a press conference ...
Breaking Medicine News(10 mins):